Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of nonfunctioning islet cell carcinomas.

D K Bartsch1, T Schilling, A Ramaswamy

  • 1Department of Surgery, Philipps-University Marburg, Baldingerstrasse, 35033 Marburg, Germany.

World Journal of Surgery
|October 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative outcomes with low-dose and standard-dose immune checkpoint inhibitors in microsatellite stable advanced gastric/gastroesophageal adenocarcinoma.

ESMO gastrointestinal oncology·2026
Same author

Geriatric Assessment-guided therapy modification and outcomes in patients with non-metastatic gastroesophageal cancer: a retrospective cohort study.

ESMO gastrointestinal oncology·2026
Same author

Corrigendum to "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer": [ESMO Open 9 (2024) 103647].

ESMO open·2025
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.

ESMO open·2024
Same author

Correlation of the Geriatric Assessment with Overall Survival in Older Patients with Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Nonfunctioning islet cell carcinomas, rare pancreatic tumors, often present with pain and jaundice. Aggressive surgery and medical therapy can achieve significant long-term palliation, despite rare curative resections.

Area of Science:

  • Endocrinology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Pancreatic islet cell tumors are rare and can be benign or malignant.
  • Nonfunctioning tumors lack characteristic clinical syndromes.
  • These tumors present a diagnostic and therapeutic challenge.

Purpose of the Study:

  • To review the clinical features, management, and outcomes of nonfunctioning islet cell carcinomas.
  • To evaluate the effectiveness of surgical and medical interventions.
  • To identify prognostic factors for survival and disease recurrence.

Main Methods:

  • Retrospective review of 18 patients with nonfunctioning islet cell carcinomas operated on between 1983 and 1998.
  • Analysis of clinical presentation, diagnostic imaging (sonography, CT, angiography, scintigraphy), surgical approach, and adjuvant therapies.

Related Experiment Videos

  • Evaluation of survival rates and disease-free survival.

    • Main Results:

    • The median age was 53.5 years; common symptoms included abdominal pain, weight loss, and jaundice.
    • Advanced disease with metastases was frequent (83% regional, 33% distant).
    • Five- and 10-year survival rates were 65.4% and 49.1%, respectively; curative resection was rare, but palliation was achievable.

    Conclusions:

    • Nonfunctioning islet cell carcinomas are often diagnosed at advanced stages.
    • An aggressive surgical approach combined with medical therapy can lead to significant long-term palliation.
    • While surgical cure is uncommon, multidisciplinary management improves patient outcomes.